

NAME	REFERENCE	FINAL AMOUNT	CHEMISTRY
siRNA Cdk-1 control siRNA duplex - human	SR-CL006-005	5 nmoles of duplex / tube	RNA
1 siRNA negative control duplex is made of two complementary strands			
Antisense strand	dTdT 3' overhang		
Sense strand	dTdT 3' overhang		
MODIFICATIONS 5' OR 3'			
None			
PURIFICATION		QC STATUS	
IEX-HPLC		Passed	

DELIVERY CONDITION

Shipped lyophilized
Additional reagent supplied : 1 ml RNase-free Water

RECONSTITUTION

To make up to 100 μ M concentration, add 50.0 μ l of recommended buffer.
To make up to 20 μ M concentration, add 250.0 μ l of recommended buffer.
To make up to 5 μ M concentration, add 1.00 ml of recommended buffer.

STORAGE CONDITION

Store siRNAs (and RNA oligos in general) as a dry pellet at $-20\text{ }^{\circ}\text{C}$ (or preferably $-70\text{ }^{\circ}\text{C}$) in a non-frost free freezer until ready to use. Once resuspended in RNase-free buffer, store at $-70\text{ }^{\circ}\text{C}$ and avoid contact with RNases. siRNA should be resuspended to a convenient stock concentration (e.g. 50 μ M), and stored in small aliquots to avoid multiple freeze thaw cycles. When stored under these conditions and using good RNase-free technique, they typically remain stable for 6 months or more. The solution can be freeze-thawed up to 5 times. For long-term storage, siRNA oligos should be kept dried.

DESCRIPTION

The Positive Control siRNAs are used to validate experimental results and to ensure that the method used is suitable to perform an RNAi assay. Positive control can also be used to normalize obtained results.

The Positive Control siRNAs consist of a duplex siRNA directed against a range of endogenous and reporter genes.

For more information, do not hesitate to contact us.

Disclaimers and trademarks:

RNA interference is licensed under European Patents 1144623, 1214945 and foreign equivalents from Alnylam Pharmaceuticals, Inc., Cambridge, USA and is provided only for use in academic and commercial research (excluding the evaluation or characterization of this product as the potential basis for a siRNA-based drug) and not for any other commercial purposes. Information about licenses for commercial use (including discovery and development of siRNA-based drugs) is available from Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142, USA.

TECHNICAL SUPPORT

If you have any questions feel free to contact us

✉ oligo@eurogentec.com

EUROPE

Kaneka Eurogentec S.A. Liège Science Park
Rue Bois Saint-Jean 5 - 4102 SERAING BELGIUM
Tel: +32(0)4 372 74 00 - Fax: +32(0)4 264 07 88
E-mail info@eurogentec.com Web: www.eurogentec.com

RPM Liège T.V.A.-(BE)-0427.348.346

NORTH AMERICA

EGT North America, Inc.
34801 Campus Drive - Fremont, CA 94555
Tel.: +1 (510) 896 -1350 * Fax: +1 (510) 791-9572
E-mail: info@eurogentec.com Web: www.eurogentec.com